Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4.
Acetamides
/ administration & dosage
Animals
Azepines
/ administration & dosage
Cell Cycle Proteins
Cell Line, Tumor
Cell Proliferation
/ drug effects
Cell Survival
/ drug effects
Female
Gene Expression Regulation, Neoplastic
/ drug effects
Gene Knockdown Techniques
Humans
Mice
Nuclear Proteins
/ genetics
Ovarian Neoplasms
/ drug therapy
Receptor, Notch3
/ metabolism
Transcription Factors
/ genetics
Xenograft Model Antitumor Assays
Journal
Molecular cancer therapeutics
ISSN: 1538-8514
Titre abrégé: Mol Cancer Ther
Pays: United States
ID NLM: 101132535
Informations de publication
Date de publication:
02 2019
02 2019
Historique:
received:
09
04
2018
revised:
24
08
2018
accepted:
06
11
2018
pubmed:
14
11
2018
medline:
26
11
2019
entrez:
14
11
2018
Statut:
ppublish
Résumé
Systematic approaches for accurate repurposing of targeted therapies are needed. We developed and aimed to biologically validate our therapy predicting tool (TPT) for the repurposing of targeted therapies for specific tumor types by testing the role of Bromodomain and Extra-Terminal motif inhibitors (BETi) in inhibiting BRD4 function and downregulating Notch3 signaling in ovarian cancer.Utilizing established ovarian cancer preclinical models, we carried out
Identifiants
pubmed: 30420565
pii: 1535-7163.MCT-18-0365
doi: 10.1158/1535-7163.MCT-18-0365
pmc: PMC6363833
mid: NIHMS1512604
doi:
Substances chimiques
Acetamides
0
Azepines
0
BRD4 protein, human
0
CPI203
0
Cell Cycle Proteins
0
NOTCH3 protein, human
0
Nuclear Proteins
0
Receptor, Notch3
0
Transcription Factors
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
421-436Subventions
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA213759
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA217685
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA096297
Pays : United States
Organisme : NCI NIH HHS
ID : R35 CA209904
Pays : United States
Organisme : NCATS NIH HHS
ID : UH3 TR000943
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA098258
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA096300
Pays : United States
Organisme : NCI NIH HHS
ID : R50 CA221675
Pays : United States
Informations de copyright
©2018 American Association for Cancer Research.
Références
Mol Cancer Ther. 2017 Jun;16(6):1114-1123
pubmed: 28265009
J Minim Invasive Gynecol. 2017 Feb;24(2):230-234
pubmed: 28007588
PLoS One. 2017 Oct 26;12(10):e0186906
pubmed: 29073279
Annu Rev Med. 2014;65:405-15
pubmed: 24422576
Clin Cancer Res. 2018 Oct 1;24(19):4845-4853
pubmed: 29941483
PLoS One. 2017 Apr 28;12(4):e0176763
pubmed: 28453553
Pharmacol Ther. 2014 Feb;141(2):140-9
pubmed: 24076266
Mol Cancer Res. 2016 Apr;14(4):324-31
pubmed: 26792867
Mol Cancer Ther. 2006 Oct;5(10):2512-21
pubmed: 17041095
Nat Rev Drug Discov. 2014 May;13(5):337-56
pubmed: 24751816
Cancer Res. 2014 Jun 15;74(12):3282-93
pubmed: 24743243
Curr Opin Obstet Gynecol. 2018 Feb;30(1):44-50
pubmed: 29227302
BMC Genomics. 2014 Dec 01;15:1044
pubmed: 25435088
Brief Bioinform. 2017 Sep 1;18(5):820-829
pubmed: 27444372
Cell. 2011 Sep 16;146(6):904-17
pubmed: 21889194
Am J Clin Pathol. 2012 Oct;138(4):535-44
pubmed: 23010708
Nature. 2016 Jan 21;529(7586):413-417
pubmed: 26735014
J Biol Chem. 2012 Mar 30;287(14):10738-52
pubmed: 22334664
Cancer Res. 2012 May 1;72(9):2294-303
pubmed: 22396495
Cancer Discov. 2018 Jan;8(1):24-36
pubmed: 29263030
Cancer Sci. 2010 Sep;101(9):1977-83
pubmed: 20624166
Gynecol Oncol. 2015 Aug;138(2):372-7
pubmed: 26050922
Cancer Res. 2016 Nov 1;76(21):6320-6330
pubmed: 27803105
Nat Rev Dis Primers. 2016 Aug 25;2:16061
pubmed: 27558151
Cell Death Dis. 2014 Oct 09;5:e1450
pubmed: 25299775
Tumour Biol. 2015 Feb;36(2):953-7
pubmed: 25315186
Biochim Biophys Acta. 2014 Sep;1839(9):813-25
pubmed: 24984200
Development. 2011 Sep;138(17):3593-612
pubmed: 21828089
Proc Natl Acad Sci U S A. 2011 Oct 4;108(40):16669-74
pubmed: 21949397
J Biol Chem. 2012 Nov 23;287(48):40360-70
pubmed: 23055528
Oncotarget. 2016 Oct 11;7(41):66809-66821
pubmed: 27572308
Mol Cancer Ther. 2016 May;15(5):1029-42
pubmed: 26939702
Cell Rep. 2016 Aug 2;16(5):1273-1286
pubmed: 27452461
Proc Natl Acad Sci U S A. 2015 Jan 6;112(1):232-7
pubmed: 25535366
Nat Struct Mol Biol. 2014 Dec;21(12):1047-57
pubmed: 25383670
Nat Genet. 2013 Jun;45(6):580-5
pubmed: 23715323
Circ Res. 2009 Feb 27;104(4):466-75
pubmed: 19150886
BMC Genomics. 2012 Jun 25;13:282
pubmed: 22732065
Front Oncol. 2016 May 02;6:108
pubmed: 27200296
Nat Rev Drug Discov. 2010 Jun;9(6):427-8
pubmed: 20514063
Proc Natl Acad Sci U S A. 2012 May 1;109(18):6927-32
pubmed: 22509028
Mol Cell. 2013 Mar 7;49(5):843-57
pubmed: 23317504
Cell Rep. 2017 Dec 19;21(12):3398-3405
pubmed: 29262321
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30
pubmed: 26742998
Cancer Res. 2005 Aug 1;65(15):6910-8
pubmed: 16061675
Leukemia. 2014 Oct;28(10):2049-59
pubmed: 24721791
Ther Adv Hematol. 2015 Jun;6(3):128-41
pubmed: 26137204
Proc Natl Acad Sci U S A. 2012 Oct 23;109(43):E2939-48
pubmed: 23019585
Mol Cancer Ther. 2014 Dec;13(12):3230-40
pubmed: 25349306
Anticancer Res. 2013 Mar;33(3):801-8
pubmed: 23482747
Theranostics. 2016 Jan 01;6(2):219-30
pubmed: 26877780
Mol Cell Biol. 2008 Feb;28(3):967-76
pubmed: 18039861